___

• Goldenberg DM. Targeted therapy of cancer with radiolabeled an- tibodies. J Nucl Med. 2002 May;43(5):693-713.
• Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.J Nucl Med. 2005 Jan;46 Suppl 1:115S-27S.
• Diagnostic nuclear medicine. Fourt edition. Chapter 47. Richard L. Wahl. Radiolabeled monoclonal antibody therapy.
• Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Golden- berg DM, Becker W. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Can- cer. 1998 Aug 31;77(5):787-95.
• Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Bo- oth BJ, Pavlinkova G, Tempero M, Batra SK. Single-Dose ver- sus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs. Clin Cancer Res. 2001 Jan;7(1):175-84.
• Honegger A. Engineering antibodies for stability and efficient fol- ding. Handb Exp Pharmacol. 2008;(181):47-68.
• Milenic DE. Radioimmunotherapy: designer molecules to potenti- ate effective therapy. Semin Radiat Oncol. 2000 Apr;10(2):139-55.
• Reilly RM. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens. J Nucl Med. 2006 Feb;47(2):196-9.
• Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol. 2007 Mar;44(8):1986-98. Epub 2006 Oct 31.
• Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003 Mar;44(3):400-11.
• Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre- Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Gol- denberg DM, Chatal JF, Barbet J. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispe- cific antibody and 131I-labeled bivalent hapten in a phase I optimi- zation clinical trial. J Nucl Med. 2006 Feb;47(2):247-55.
• Barendswaard EC, Humm JL, O’Donoghue JA, Sgouros G, Finn RD, Scott AM, Larson SM, Welt S. Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a hu- man colon cancer xenograft. J Nucl Med. 2001 Aug;42(8):1251-6.
• Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, Davodeau F, Cherel M. Cancer radioimmu- notherapy with alpha-emitting nuclides.Eur J Nucl Med Mol Ima- ging. 2005 May;32(5):601-14.
• Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled mo- noclonal antibodies.Nucl Med Biol. 2007 Oct;34(7):779-85. Epub 2007 May 11.
• Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213- lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010 Nov 1;16(21):5303-11.
• Park JA, Kim JY. Recent advances in radiopharmaceutical app- lication of matched-pair radiometals. Curr Top Med Chem. 2013 Feb 1;13(4):458-69.
• Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant. 2005 Dec;36(12):1021-6.
• Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin radioimmunotheraphy dosimetry result in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000;27:766-77.
• Chong HS, Milenic DE, Garmestani K, Brady ED, Arora H, Pfiester C, Brechbiel MW. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy. Nucl Med Biol. 2006 May;33(4):459-67. Epub 2006 May 2.
• Wahl RL, Kroll S, Zasadny KR. Patient specific whole-body dosi- metry: principles and a simplified method for clinical implementa- tion. J Nucl Med 1998;39:14S-20S.
• Barbet J, Kraeber-Bodéré F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999 Jun;14(3):153-66.
• Marcus R. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma. Semin Oncol. 2005 Feb;32(1 Suppl 1):S36-43.
• Zhang MM, Gopal AK. Radioimmunotherapy-based conditio- ning regimens for stem cell transplantation. Semin Hematol. 2008 Apr;45(2):118-25.
• Bischof Delaloye A. The role of nuclear medicine in the treatment of non-Hodgkin’s lymphoma (NHL). Leuk Lymphoma. 2003;44 Suppl 4:S29-36.
• Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti CD20 monoclonal antibody theraphy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-70.
• Wiseman GA, White CA, Sparks RB, Erwin WD gh BR. Biodist- ribution and dosimetry results from a phase III prospectively rand omized controlled trial of Zevalin radioimmunotherapy for low- grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):181-94.
• Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan ex- perience. Blood. 2000 Aug 15;96(4):1259-66.
• Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Feh- renbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM. Pivotal study of iodine I 131 tositumo- mab for chemotherapy-refractory low-grade or transformed low- grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001 Oct 1;19(19):3918-28.
• Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, et al. Phase II tri- al of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995 Aug 5;346(8971):336-40.
• Forrer F, Oechslin-Oberholzer C, Campana B, Herrmann R, Ma- ecke HR, Mueller-Brand J, Lohri A.Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other In- dolent B-Cell Lymphomas. J Nucl Med. 2013 Apr 9. (Epub ahe- ad of print)
• Vriesendorp HM, Quadri SM. Radiolabeled immunoglobulin the- rapy in patients with Hodgkin’s disease. Cancer Biother Radiop- harm. 2000 Oct;15(5):431-45.
• Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant. 2005 Dec;36(12):1021-6.
• Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant. 2005 Dec;36(12):1021-6.
• Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colc- her D, Horak ID, Weiner LM. Phase II trial of yttrium 90-DOTA- biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406-14.
• Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Ya- mauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA. A Phase I trial of 90Y-anti- carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5842-52.
• Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Rau- bitschek AA. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm. 2006 Apr;21(2):88-100.
• Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, Austin JM Jr, Kilgore LC, Grizzle WE, Schlom J, Lo- Buglio AF. Intraperitoneal radioimmunochemotherapy of ova- rian cancer: a phase I study. Cancer Biother Radiopharm. 2001 Aug;16(4):305-15.
• Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin Can- cer Res. 2007 Sep 15;13(18 Pt 2):5643s-5645s.
• Seidl C, Essler M. Radioimmunotherapy for peritoneal cancers. Immunotherapy. 2013 Apr;5(4):395-405.
• Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclo- nal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther. 2007 May;7(5):675-87.
• Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach.Eur J Nucl Med. 2000 May;27(5):601-9.
• Sorumlu yazar: Dr. Salih Sinan Gültekin
• Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi,
• 1 Nükleer Tıp Bölümü, Ankara
• Gsm: 0 533 761 49 91
• E-mail: gultekinsinan@gmail.com
• Acil Hipertansiyon ve Hipertansif Krizde Tedavi Stratejileri
• Ramazan COŞAR1, Serap BİBEROĞLU², Aydın ÇİFCİ1
• ¹ Kırıkkale Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Kırıkkale, TÜRKİYE
• ² Kırıkkale Yüksek İhtisas Hastanesi, Acil Tıp Uzmanı, Kırıkkale, TÜRKİYE
• Geliş Tarihi: 22.07.2013
• Kabul Tarihi: 20.12.2013
• Chobanian, A.V., et al., Seventh report of the Joint National Com- mittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003. 42(6): p. 1206-52.
• Kearney, P.M., et al., Global burden of hypertension: analysis of worldwide data. Lancet, 2005. 365(9455): p. 217-23.
• Altun, B., et al., Prevalence, awareness, treatment and control of hypertension in adults with chronic kidney disease in Turkey: re- sults from the CREDIT study. Kidney Blood Press Res, 2012. 36(1): p. 36-46.
• Sarafidis, P.A., N. Khosla, and G.L. Bakris, Antihypertensive the- rapy in the presence of proteinuria. Am J Kidney Dis, 2007. 49(1): p. 12-26.
• Rosei, E.A., M. Salvetti, and C. Farsang, European Society of Hypertension Scientific Newsletter: treatment of hypertensive ur- gencies and emergencies. J Hypertens, 2006. 24(12): p. 2482-5.
• Khot, U.N., et al., Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med, 2003. 348(18): p. 1756-63.
• Robin, E.D. and R. McCauley, Nitroprusside-related cyanide po- isoning. Time (long past due) for urgent, effective interventions. Chest, 1992. 102(6): p. 1842-5.
• Hall, V.A. and J.M. Guest, Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulfate prophylaxis. Am J Crit Care, 1992. 1(2): p. 19-25; quiz 26-7.
• Gray, R.J., Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker. Chest, 1988. 93(2): p. 398- 403.
• Grossman, E., A.N. Ironi, and F.H. Messerli, Comparative tolera- bility profile of hypertensive crisis treatments. Drug Safety, 1998. 19(2): p. 99-122.
• Varon, J. and P.E. Marik, Clinical review: the management of hypertensive crises. CRITICAL CARE-LONDON-, 2003. 7(5): p. 374-384.
• Haas, A.R. and P.E. Marik, Current diagnosis and management of hypertensive emergency. Semin Dial, 2006. 19(6): p. 502-12.
• Curran, M.P., D.M. Robinson, and G.M. Keating, Intravenous ni- cardipine: its use in the short-term treatment of hypertension and various other indications. Drugs, 2006. 66(13): p. 1755-82.
• Karnik, N.D., et al., Nifedipine, captopril, metoprolol and nifedipi- ne with metoprolol in hypertensive crisis in non-intensive care set- ting. J Assoc Physicians India, 1996. 44(7): p. 480-2.
• Sorumlu Yazar: Dr. Aydın ÇİFCİ
• Kırıkkale Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim
• Dalı, Kırıkkale, TÜRKİYE
• Gsm: 0 531 929 17 05
• E-mail: dr.aydin.71@hotmail.com Vaka Sunumu
• Ampisilin - Sulbaktam Tedavisi Sonrasında Stevens - Johnson
• Sendromu Gelişen Olguda E.coli Sepsisi
• Salih CESUR1, Nilgün ALTIN², Göknur YAPAR TOROS³, Ethem ÇELİK4, Sani Namık MURAT4, Kamer KOLDAŞ5,
• Gülkan SOLGUN³, İrfan ŞENCAN², Sami KINIKLI1
• ¹ Ankara Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara
• ² Dışkapı Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara
• ³ Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara
• 4 Ankara Eğitim ve Araştırma Hastanesi,Kardiyoloji Kliniği, Ankara
• 5 Yenimahalle Devlet Hastanesi, Mikrobiyoloji Laboratuvarı, Ankara dicine 2008; 40: 129-38.
• Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taiteb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 2000; 83: 347-52.
• Tükenmez G, Mansur AT, Tütüncü D, Serdar ZA, Aydıngöz İE. Toksik epidermal nekrolizde intravenöz immunglobulin tedavisi: İki olgu sunumu. Türk Dermatoloji Dergisi 2005;39(2): 136-141.
• Raucci U, Rossi R, Da Cas R, Rafaniello C, Mores N, Bersani G,et al. Stevens-johnson syndrome associated with drugs and vaccines in children: a case-control study. PLoS One. 2013; 8(7): e68231.
• Thammakumpee J, Yongsiri S. Characteristics of toxic epidermal necrolysis and Stevens-Johnson syndrome: a 5-year retrospective study. J Med Assoc Thai. 2013; 96(4):399-406.
• Fathallah N, Hanen Z, Slim R, Boussofara L, Najet G, Bouraoui K, Ben Salem C. Co-amoxiclav-induced Stevens Johnson syndro- me in a child. Pan Afr Med J. 2013;14:38.
• Weinand C, Xu W, Perbix W, Lefering R, Maegele M, Rathert M, Spilker G. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analy- sis of mortality risk for causative agents
• Arca E, Köse O, Erbil AH, Nişanci M, Akar A, Gür AR. A 2-year- old girl with Stevens--Johnson syndrome/toxic epidermal necroly- sis treated with intravenous immunoglobulin. Pediatr Dermatol. 2005 ; 22(4):317-20
• Sorumlu Yazar: Doç. Dr. Salih CESUR,
• Ankara Eğitim ve Araştırma Hastanesi,
• Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Cebeci-Ankara
• E-mail: scesur89@yahoo.com